Skip to content

Advertisement

Open Access

Erratum to: Romidepsin for the treatment of relapsed/refractory peripheral T cell lymphoma: prolonged stable disease provides clinical benefits for patients in the pivotal trial

  • Francine Foss1Email author,
  • Steven Horwitz2,
  • Barbara Pro3,
  • H. Miles Prince4,
  • Lubomir Sokol5,
  • Barbara Balser6,
  • Julie Wolfson6 and
  • Bertrand Coiffier7
Journal of Hematology & Oncology201710:154

https://doi.org/10.1186/s13045-017-0518-8

Received: 21 July 2017

Accepted: 14 August 2017

Published: 18 September 2017

The original article was published in Journal of Hematology & Oncology 2016 9:22

Erratum

The original article [1] contains an error whereby Fig. 2a & b are mistakenly interchanged and contain incorrect colour-coding.
Figure 1
Fig. 2:

Survival based on clinical IRC assessment by best response to romidepsin (n = 130). Progression-free survival (a) and overall survival (b). Patients with insufficient efficacy data to determine response due to early termination (NE; n = 29) were included as nonresponders. NE not evaluable

The correct versions of Fig. 2a & b are thus displayed below.

Notes

Declarations

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
Yale Cancer Center, New Haven, USA
(2)
Memorial Sloan-Kettering Cancer Center, New York, USA
(3)
Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, USA
(4)
Peter MacCallum Cancer Centre, University of Melbourne, Melbourne, Australia
(5)
Moffitt Cancer Center, Tampa, USA
(6)
Veristat, LLC, Southborough, USA
(7)
Hospices Civils de Lyon, Lyon, France

Reference

  1. Foss F, et al. Romidepsin for the treatment of relapsed/refractory peripheral T cell lymphoma: prolonged stable disease provides clinical benefits for patients in the pivotal trial. J Hematol Oncol. 2016;9:22.View ArticlePubMedPubMed CentralGoogle Scholar

Copyright

© The Author(s). 2017

Advertisement